Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

Related: Patients start to see savings, ahead of IRA's Medicare drug ... GLP-1 agonists for help with controlling diabetes, but federal law prohibits Medicare from covering weight-loss drugs.

Of them, about 5,600 had a prescription for a GLP-1 medication. The study authors stated that people with alcohol use disorder who take a weight-loss drug had ... the highest number on record.

However, the study had a relatively small number of participants and ... different factors can impact a person’s weight loss while on a GLP-1 drug. For example, in other GLP-1 drug trials ...

It was semaglutide, a drug sold under the brand names Ozempic (for diabetes) and Wegovy (for weight loss). Following ...

The demand for bariatric operations dropped sharply last year as use of anti-obesity drugs such as Wegovy surged, study finds ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

Since the U.S. Food and Drug Administration approved Wegovy (the first GLP-1 medicine aimed at weight ... weight regain." ...

Kentucky, Alaska and Alabama are the three states where weight loss drugs ... U.S. Food and Drug Administration (FDA) approved the semaglutide-based drug Wegovy for obesity. Before Wegovy, 190,000 ...

Broadening access to highly effective weight-loss drugs could prevent more than 40,000 deaths each year in the United States.

Poorer folks’ access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.O ...

Welcome to the healthier, happier world of 2030. Heart attacks and strokes are down 20%. A drop in food consumption has left ...